The Global Eye Allergy Treatment Market is expected to grow at the CAGR of ~5.2% during the forecast
period and estimated to reach US$ 6845.3million by 2023.
The Global Eye Allergy Treatment Market has been evaluated as a moderately growing market and it is
expected to continue growing in the near future. Increasing prevalence of various eye allergies,
development of advanced diagnostic and treatment devices, increasing adoption of new products and
therapies, and new FDA and other approvals are driving the market.
The market for eye allergy treatment was around USD 4800.5 million in 2016 and is expected to reach USD
6845.3 million which is projected to grow at a CAGR of 5.2% by 2023.
Major players in Eye allergy treatment market:
There are plenty of large and small market players which operate in this market: ALLERGAN (Republic of
Ireland), Johnson & Johnson Vision Care, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland),
Pfizer Inc. (US), Regeneron Pharmaceuticals, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Santen
Pharmaceutical Co., Ltd.(Japan), Valeant (Canada) Shire (Republic of Ireland), and others.
Top pharmaceutical companies are dominating this market due to various factors such as strong global
presence, sales and distribution network, investment in R&D, high quality products, and strong brand image.
In 2016, Irish pharmaceutical giant Shire received U S Food and Drug Administration (FDA) approval for
their dry-eye disease drug, this drug is marketed under the brand name Xiidra.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/3811 .
Segmentation:
Global Eye Allergy Treatment Market has been segmented on the basis of type which comprises of seasonal
and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic
conjunctivitis, giant papillary conjunctivitis, and others. Vernal keratoconjunctivitis includes palpebral,
limbal, corneal, and others.
On the basis of treatment, the market has been segmented into medication, allergy shots (immunotherapy),
and others. Medication includes artificial tears, decongestants, oral antihistamines, antihistamine/mast-cell
stabilizers, corticosteroids. Decongestants are further sub-segmented into with or without antihistamines.
Allergy shots (immunotherapy) is sub-segmented into Subcutaneous Immunotherapy Treatment (SCIT) and
Sublingual Immunotherapy Treatment (SLIT).
On the basis of end user, it is segmented into eye hospitals & clinics, medical institutes, research centers,
and others.
Regional Analysis:
Considering the global scenario of the Eye Allergy Treatment Market. America is top revenue generator in
global market that is mainly due to some factors like new FDA approvals, aggressive strategies by
pharmaceutical companies, increasing investment for R&D as well as clinical trials. European market is the
second largest market for eye allergy treatment. Increasing prevalence and growing awareness of eye
allergies and its treatments are leading the growth of Asia Pacific eye allergy treatment market. Middle East
and Africa eye allergy treatment market is expected to have limited growth because of lack of traditional
healthcare practices and slow adoption of new products and therapies.
Browse Complete Premium 76 Pages Research Report Enabled with Respective Tables and
Figures is Available @ https://www.marketresearchfuture.com/reports/eye-allergy-treatment-market-
3811 .
Major TOC for Eye Allergy Treatment Market